| Autor: |
Charafeddine KM; Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon., Mahfouz RA, Ibrahim GY, Taher AT, Hoballah JJ, Taha AM |
| Jazyk: |
angličtina |
| Zdroj: |
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis [Clin Appl Thromb Hemost] 2010 Oct; Vol. 16 (5), pp. 594-8. Date of Electronic Publication: 2009 Jun 10. |
| DOI: |
10.1177/1076029609334629 |
| Abstrakt: |
Factor V Leiden (Factor V G1691A), prothrombin gene mutation G20210A, and homozygous C677T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene are known to predispose venous thromboembolism (VTE). We present herein a rare case of a young woman heterozygous for these mutations and taking oral contraceptive pills for less than 2 months, diagnosed to have massive deep venous thrombosis and bilateral pulmonary embolism. The patient was managed for 10 days in the hospital and discharged home on oral anticoagulants. This case suggests that screening for these factors in people with family history of thrombosis and in relatives of patients with these mutations is highly recommended to prevent fatal consequences. In addition, a new guideline for treatment and prophylaxis with anticoagulant for these patients and others who are at risk of developing VTE (American College of Chest Physicians [ACCP] guidelines-Chest 2008) has been published recently. Our recommendation is to promote for the internationally published algorithms through their application, where necessary, to prevent any future thrombotic morbidity or mortality incidents. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
